Metoject

Methotrexate, the active ingredient in Metoject, is an antimetabolite (folate antagonist) presented as a subcutaneous injection for subcutaneous use. It is employed as an immunosuppressant and antineoplastic agent in a range of autoimmune and cancer conditions. GNH USA supplies Metoject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate acts on rapidly dividing cells and immune pathways, making it useful for several inflammatory and malignant diseases. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin lesions and plaque formation. - Acute lymphoblastic leukemia: interferes with leukemic cell proliferation. - Non‑Hodgkin lymphoma: induces cytotoxicity in malignant lymphocytes. - Ectopic pregnancy: halts trophoblastic growth to allow non‑surgical resolution.

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting: mild to moderate gastrointestinal upset. - Fatigue: persistent tiredness unrelated to activity level. - Oral mucositis: soreness or ulceration of the mouth lining. - Elevated liver enzymes: mild hepatic irritation detectable on labs. - Alopecia: temporary thinning or loss of scalp hair. - Skin rash: mild erythema or itching.

Serious or Rare Side Effects: - Bone marrow suppression: pancytopenia leading to infection risk. - Pulmonary toxicity: interstitial pneumonitis presenting with cough and dyspnea. - Severe hepatotoxicity: fibrosis or cirrhosis with prolonged use. - Renal impairment: acute kidney injury due to precipitation of drug crystals. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should assess baseline organ function and counsel patients on potential risks. - Pregnancy contraindication: avoid use in pregnancy due to teratogenicity. - Breastfeeding restriction: do not breastfeed while receiving methotrexate. - Renal function monitoring: adjust dose if creatinine clearance is reduced. - Hepatic monitoring: perform regular liver function tests. - Infection vigilance: monitor for signs of immunosuppression. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Methotrexate interacts with several drug classes that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate serum levels and risk of toxicity. - Proton pump inhibitors (e.g., omeprazole): may reduce renal clearance, heightening adverse effects. - Trimethoprim‑sulfamethoxazole: potentiates bone marrow suppression.

Moderate Interactions (Monitor Closely): - Penicillins (high‑dose): may modestly increase methotrexate concentrations. - Sulfonamides: can impair renal elimination. - Live vaccines: risk of uncontrolled infection due to immunosuppression.